Boehringer Ingelheim Reports 16.6% Weight Loss in Late-Stage Trial of Obesity Drug

In a recent development, Boehringer Ingelheim announced that its experimental obesity drug survodutide achieved an average weight loss of up to 16.6% in a Phase III clinical trial. The results relate to a 76-week study involving obese or overweight adults without type 2 diabetes, with participants receiving the drug showing significantly greater weight reduction compared to a placebo group, which recorded a 3.2% decrease.

Boehringer Ingelheim holds the rights to develop and commercialise the experimental obesity drug survodutide under a 2011 licensing agreement with Zealand Pharma, which is entitled to royalty payments on global revenue.

The trial, known as SYNCHRONIZE-1, met its primary objective and full results are scheduled to be presented at the American Diabetes Association’s 2026 Scientific Sessions.

Survodutide works by mimicking two gut hormones, GLP-1, which suppresses appetite, and glucagon, which may affect liver fat and metabolic processes. Shashank Deshpande stated that the glucagon component may help differentiate the drug by improving the quality of weight loss, including reductions in metabolically harmful visceral fat.

While the findings demonstrate efficacy, additional data on safety, side effects, and long-term outcomes remain to be disclosed. These factors are expected to play a key role in forthcoming regulatory and commercial assessments of the drug.